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Efficacy of a multi-component exercise
programme and nutritional
supplementation on musculoskeletal health
in men treated with androgen deprivation
therapy for prostate cancer (IMPACT): study
protocol of a randomised controlled trial
Patrick J. Owen1*, Robin M. Daly1, Patricia M. Livingston2, Niamh L. Mundell1, Jack Dalla Via1, Jeremy L. Millar3
and Steve F. Fraser1
Abstract
Background: Prostate cancer is the most commonly diagnosed cancer in men in developed countries. Androgen
deprivation therapy (ADT) is a systemic treatment shown to increase survival in selected patients with prostate
cancer. The use of ADT continues to increase for all stages and grades of prostate cancer despite known treatment-
induced adverse effects. The primary aim of this study is to examine the efficacy of a targeted, multi-component
resistance and impact-loading exercise programme together with a daily protein-, calcium- and vitamin D-enriched
supplement on bone health in men treated with ADT for prostate cancer. Secondary aims are to determine the
effects of this intervention on measures of total body and regional body composition, cardiometabolic risk,
inflammatory markers, health-related quality of life and cognitive function.
Methods: This study is a two-arm randomised controlled trial. Men currently treated with ADT for prostate cancer
will be randomised to either a 52-week, community-based, exercise training and nutritional supplementation
intervention (n = 51) or usual care control (n = 51). Participants will be assessed at baseline, 26 weeks and 52 weeks
for all measures. The primary outcome measures are proximal femur and lumbar spine areal bone mineral density
(BMD). Secondary outcomes comprise: changes in tibial and radial bone structure and strength, total body and
regional body composition, muscle strength and function, as well as cardiometabolic health, catabolic/inflammatory
and anabolic/anti-inflammatory cytokines, health-related quality of life and cognitive function.
Discussion: This study investigates whether a multi-component intervention incorporating a targeted bone and
muscle-loading programme in combination with a protein-, calcium- and vitamin D-enriched supplement can
ameliorate multiple adverse effects of ADT when compared to usual care. The results will contribute to the
development of exercise training and nutrition guidelines for optimising overall health in men treated with ADT for
prostate cancer.
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Background
In Australia, as in other developed countries, prostate
cancer (PCa) is the most commonly diagnosed cancer in
men [1]. Approximately 1.1 million new cases of PCa
are diagnosed worldwide each year [1]. In Australia, a
2014 report estimated that approximately 13% of cancer-
related deaths in men were attributed to PCa, which
ranks second to lung cancer as the most common cause
of cancer-related death in men [2]. Due to medical ad-
vancements in both the screening and treatment of PCa,
5-year relative survival rates of all PCa cases are now ap-
proaching 100% internationally [3], and thus these pa-
tients are living longer, but are susceptible to potential
age-related and treatment-related declines in health.
Therefore, the clinical paradigm is shifting to an in-
creased focus on improving the quality of years lived.
Various modalities of androgen deprivation therapy
(ADT), including those administered as neoadjuvant or
adjuvant therapies with other treatments, are commonly
used to treat PCa as it improves overall survival, particu-
larly in men with advanced PCa [4–7]. However, the evi-
dence that ADT prolongs survival in men with localised
PCa remains limited and, therefore, debated [8, 9]. Des-
pite this lack of evidence, the use of ADT continues to
increase for all stages and grades of PCa [10]. It was esti-
mated that approximately 23,500 Australian men re-
ceived pharmacological ADT via gonadotropin-releasing
hormone (GnRH) agonists in 2008–2009 [11]. After re-
peating this analysis for 2013–2014, we estimated that
approximately 25,500 men are currently receiving ADT
via GnRH agonists [12]. Thus, ADT remains the most
common cause for severe hypogonadism in men in
Australia.
Despite benefits in overall survival in appropriately se-
lected men, the hypogonadism induced via ADT has been
associated with numerous adverse effects, particularly with
regard to musculoskeletal and cardiometabolic health. It
has been reported that within the first 3 to 12 months of
ADT, men experience a rapid and dramatic loss in bone
mass (up to 11%) and concomitant losses in muscle mass
(2–5%) [13–17] which may explain the observed 23–65%
increased fracture risk in this group [18–20]. There is also
a profound gain (up to 15%) in fat mass (FM) which likely
contributes to the 10–45% reported increased risk of dia-
betes, coronary heart disease, myocardial infarction and
sudden cardiac death [13, 17, 21–25]. Thus, there is a need
to develop safe and effective interventions to manage the
multiple treatment-induced adverse effects of ADT in men
with PCa.
Exercise training has been strongly suggested as a vi-
able intervention to ameliorate many of the adverse ef-
fects of ADT [17, 26–28]. In terms of musculoskeletal
health outcomes, a number of interventions have shown
that progressive resistance training (PRT) can increase
muscle strength [29–33], muscle endurance [30, 34] and
balance [30] in men treated with ADT. While there is
also some evidence that PRT can improve or preserve
lean body mass (LBM) [30, 32, 33, 35], a systematic re-
view found that there was inconclusive findings on the
effects of exercise training in men treated with ADT on
bone health [26]. To date, only four studies have exam-
ined the efficacy of exercise training on areal bone min-
eral density (aBMD) in ADT-treated men, three of which
were conducted over interventional periods of no longer
than 20 weeks and observed no benefit [32, 36, 37]. This
is perhaps not unexpected given that the typical bone re-
modelling cycle and new steady state that is measurable
takes 6–8 months to complete, and thus it is unlikely that
any true physiological skeletal adaptations would occur
prior to this period. However, a recent 12-month rando-
mised controlled trial (RCT) also reported no marked
skeletal benefits of a targeted PRT and impact-loading ex-
ercise programme in men treated with ADT [36]. This
may be due to a number of factors. First, the sample size
of approximately 25 per group was below the target sam-
ple which may have limited the power to detect any
between-group differences. Second, the impact exercise
programme was non-progressive and only consisted of
two-footed jumps (plus 10% body weight), and thus did
not incorporate diverse loading patterns which are known
to be important for bone remodelling. Third, the mean
calcium intake was < 750 mg/day, well below the recom-
mended dietary intake of 1200 mg/day. There is some evi-
dence that insufficient calcium intakes can attenuate the
skeletal responses to exercise in older adults [38]. Finally,
this study was limited to an assessment of aBMD by dual-
energy X-ray absorptiometry (DXA), which provides no
information on other determinants of bone strength (e.g.
trabecular volumetric BMD (vBMD), cortical structure),
which may change following exercise training, independ-
ent of aBMD. This is important because the findings from
a prospective study using high-resolution, peripheral,
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quantitative computed tomography (pQCT) found that
treatment with ADT for 12 months was associated with
losses of up to 11.3% in cortical and 3.5% in trabecular
vBMD, which are two- to three-fold greater than changes
observed in DXA aBMD [14]. In healthy older men, the
findings from an 18-month RCT found that a targeted
and progressive multi-component exercise programme in-
corporating PRT and a diverse range of weight-bearing,
impact activities was safe and effective for improving lum-
bar spine trabecular vBMD and femoral neck aBMD,
cross-sectional area and strength as well as muscle
strength, mass and size [39]. Further long-term RCTs are
required to examine whether similar well-designed and
progressive multi-component exercise programmes in
combination with adequate nutrition can ameliorate bone
and muscle loss in men treated with ADT for PCa.
Clinical guidelines for optimising bone health in men
on ADT recommend calcium and vitamin D treatment
[11]. While direct evidence from RCTs to support their
role in preventing bone loss in this group is lacking, a
review based on secondary analyses of clinical trials re-
ported that treatment with 500–1000 mg/day of calcium
and 200–500 IU/day of vitamin D in ADT-treated men
was inadequate to prevent bone loss [40]. In healthy
older adults, there is level-1 evidence that calcium
(>1000 mg/day) plus vitamin D (> 800 IU/day) can re-
duce fracture risk [41]. Studies have also shown that
2000 IU/day of vitamin D can improve muscle strength
and function [41, 42], and that daily consumption of
calcium-vitamin D fortified milk for 2 years prevented
aBMD loss at multiple sites in healthy men aged older
than 50 years [43]. While a systematic review and meta-
analysis of prospective studies reported that increased
dairy or calcium intake was associated with an increased
risk of PCa, no association was observed with supple-
mental or non-dairy calcium, which suggest that other
components of dairy rather than fat and calcium may in-
crease PCa risk [44]. In line with these mixed findings,
supplementation at doses < 1500 mg/day have been
shown to either have no influence on PCa progression
[45], reduce PCa risk [46] or decrease PSA velocity [47].
In addition, in men diagnosed with PCa, total milk/dairy
intake after diagnosis was not associated with a greater
risk of lethal PCa, with evidence of a decreased risk in
those with a high intake of low-fat dairy [48].
There is also evidence that increased dietary protein in
older adults can have favourable effects on both health,
particularly when combined with calcium and vitamin D
at recommended levels [38]. This has been attributed to
several factors: a higher protein intake can increase
serum insulin-like growth factor-1 (IGF-1), enhance in-
testinal calcium absorption, suppress parathyroid hor-
mone levels as well as increase muscle mass and
strength, which may improve bone health via increased
loading on bone [49]. There is also evidence in older
adults without PCa that higher protein intakes (> 1.2 g/
kg) can enhance weight loss, offset muscle loss, improve
lipid profiles and insulin sensitivity [50]. While this is
not a universal finding, this could be explained by the
modest level of protein intake achieved in some studies
and/or the type (quality) of protein consumed. Currently
there are no guidelines with regard to dietary protein for
men with PCa using ADT.
It is well known that PRT stimulates muscle protein
synthesis (MPS), but in a fasted state it also accelerates
muscle protein breakdown (MPB) [51]. Ingestion of a
high-quality, rapidly digested, protein-rich source, such
as whey-protein, post-exercise can attenuate the increase
in MPB and stimulate MPS to enhance the anabolic ben-
efits of PRT [51]. Thus, combining PRT with whey-
protein ingestion may represent an optimal strategy to
enhance muscle hypertrophy. While questions still re-
main in terms of the optimal dose of protein needed to
elicit a synergistic response with PRT, emerging evidence
indicates that 20–40 g of high-quality protein be con-
sumed early after a bout of PRT to enhance muscle mass
and/or strength [51]. Moreover, Hanson et al. [52] re-
cently demonstrated that consumption of 40 g of whey-
protein alone, or following a single session of unilateral
knee extension exercises, increased MPS beyond basal
rates in men treated with ADT; albeit these increments
were suboptimal when compared to healthy, age-
matched men. However, a critical, but as yet un-
answered, question is whether ingestion of a whey-
protein-, vitamin D- and calcium-enriched drink with
PRT can improve the multiple musculoskeletal health
outcomes in ADT-treated men.
Therefore, the primary aim of this 12-month RCT is
to determine whether a multi-component exercise
programme targeting muscle and bone health combined
with a protein-, calcium- and vitamin D-enriched drink
can enhance hip and lumbar spine aBMD in men with
PCa currently treated with ADT. The secondary aims
are to examine the effects of the intervention on tibial
and radial bone structure and strength, total body and
regional body composition, muscle strength and func-
tion, as well as cardiometabolic health, catabolic/inflam-
matory and anabolic/anti-inflammatory cytokines,
health-related quality of life (HR-QoL) and cognitive
function.
Methods
Study design
This will be a 52-week, single-blinded, two-arm RCT
consisting of a supervised and structured multi-
component exercise programme in combination with a
daily nutritional supplement. Men treated with ADT will
be randomised to either an intervention consisting of a
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multi-component exercise programme and a daily pro-
tein-, calcium- and vitamin D-enriched supplement (n =
51) or a usual care control group (n = 51). Men allocated
to usual care will not receive a placebo drink as typical
ingredients used to develop a placebo drink (e.g. malto-
dextrin as a food additive) have the potential to alter
blood glucose levels and muscle mass. A factorial 2 × 2
trial will not be conducted for several reasons: (1) the
large sample size that would be required to detect an
interaction and (2) findings from previous research in
older adults which indicates that the benefits of exercise
training on musculoskeletal health require adequate nu-
trition (e.g. dietary calcium > 1000 mg/day) [38]. This
study will not evaluate whether the combination of pro-
tein, calcium and vitamin D with exercise training is
more effective than either of these treatments alone, but
will determine if combining the two approaches is effect-
ive for improving multiple health outcomes. This trial
will be managed by the Institute for Physical Activity
and Nutrition at Deakin University. The study has been
approved by the Human Research Ethic Committees at
Deakin University (HREC 2013-184) and Alfred Health
(Project No: 455/15) and is registered with the Austra-
lian and New Zealand Clinical Trials Registry
(ACTRN12614000317695). A summary of trial resgistra-
tion data and compliance with SPIRIT guidelines are
shown in Additional files 1 and 2, respectively.
Participants
Eligible participants will be men aged 50–85 years who are
currently treated with ADT for histologically diagnosed
PCa. Treatment with ADT must be pharmacological (surgi-
cal orchiectomy excluded) and administered for longer than
12 weeks at enrolment. Participants will be excluded if they
do not have the ability to complete surveys in the English
language, have any disorder known to affect bone, calcium
or vitamin D metabolism (other than hypogonadism), are
currently receiving pharmacological intervention known to
affect bone metabolism (other than ADT), have supple-
mented with protein, calcium (> 600 mg/day) or vitamin D
(> 1000 IU/day) in the past 3 months, have undertaken PRT
(more than one session/week) or regular weight-bearing,
impact exercise (> 150 min/week) in the past 3 months, are
current smokers, have a weight greater than 159 kg, have
plans to travel for longer than 6 weeks continuously within
the following 52 weeks or have any absolute contraindica-
tions to exercise training (e.g. musculoskeletal, cardiovascu-
lar or neurological disorders) according to the American
College of Sports Medicine guidelines [53].
Recruitment and screening
Participants will be recruited via direct referral from cli-
nicians across various hospitals, private practices and
health networks in combination with promotion via PCa
support groups and advertisements in state/local news-
papers within Melbourne and surrounding areas in
Victoria, Australia. The direct referral process will in-
clude mass mail-outs to potential participants and face-
to-face discussions during regular consultations with
physicians/specialists. PCa support groups will be ini-
tially contacted via email with information regarding the
study, with an option to provide a brief presentation to
groups interested. All potential participants will be
screened initially via telephone to determine their eligi-
bility based on the criteria outlined above. All eligible
participants will be required to obtain medical approval
from their physician and provide informed consent be-
fore participating in the study.
Randomisation and blinding
Randomisation will be at the level of the individual par-
ticipant following baseline testing, stratified by age (< 65
or ≥ 65 years) and Body Mass Index (< 30 or ≥ 30 kg/m2),
using a computer-generated, random number sequence
by an independent researcher. Due to limited funding,
neither the participants nor researchers involved in the
testing will be blinded to the group allocation, with the
exception of the DXA and pQCT scans which will be
assessed independently. A flow diagram of the study
protocol is outlined in Fig. 1.
Intervention group
Multi-component exercise programme
The 52-week exercise programme will consist of two
gym-based sessions and one home-based session per
week. During the first 26 weeks, the two gym-based ses-
sions will be supervised by an accredited exercise physi-
ologist (tertiary-trained exercise professional) in a
community-based health and fitness facility. For the final
26 weeks, only one gym-based session will be supervised.
All home-based sessions will be unsupervised and per-
formed in the participant’s own time. All intervention-
group participants will be provided with a yearly
membership at a community-based health and fitness
centre and will have the opportunity to complete their
home-based sessions in this setting at their own
discretion.
The exercise training programme is a multi-
component programme that will follow key training
principles of specificity and progressive overload and will
be individually tailored to the participant’s health and
functional status. The programme will follow similar ex-
ercise prescription guidelines in terms of the structure,
type and dose (frequency, sets, repetitions, intensity) of
training to our previous ‘Osteo-cise: Strong Bones for
Life’ community-based osteoporosis prevention exercise
programme in healthy older adults in which we observed
significant improvements in musculoskeletal health and
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function (Table 1) [39, 54, 55]. To ensure progressive
overload and promote a sense of achievement for the
men, the 52-week programme will be divided into five
mesocycles (training phases). The first mesocycle (4
weeks – adoption phase) will focus on orientation to the
exercise programme, with an emphasis on correct tech-
nique. The four subsequent 12-weekly mesocycles will
focus on progression through three 4-weekly micro-
cycles (preparatory phase, challenge phase and consoli-
dation phase). Each gym-based session (approximately
60 min) will consist of a warm-up and cool-down and a
combination of aerobic training, PRT, weight-bearing,
impact activities and challenging balance/functional ex-
ercises. More specific details about each training compo-
nent are provided below.
Aerobic training
For the aerobic exercise, participants will be prescribed
15 to 25 min of continuous aerobic training at 55–75%
of predicted heart rate maximum via modalities such as
stationary cycling, treadmill walking or rowing. The type
of aerobic exercise prescribed will be based on each par-
ticipant’s preference and functional capabilities.
Progressive resistance training
For PRT, participants will be prescribed five or six tar-
geted hip, spine and forearm resistance exercises using
machine and free weights (two sets of 12–15 repetitions
at moderate intensity (3-4 on the 10-point Rating of Per-
ceived Exertion (RPE) scale) for each exercise for the
first 4-8 weeks, progressing to two sets of 8–12 repeti-
tions at moderate to hard intensity (4–6 on the RPE
scale) thereafter; resistance will be increased as tolerated
to maintain intensity and ensure progressive overload).
During the first mesocycle, five resistance exercises will
be available to choose from for each training session (leg
press, bench press, one hip-targeted, one-spine targeted
and one upper body exercise). New resistance exercises
will be introduced at the start of each subsequent meso-
cycle (three hip-targeted, three spine-targeted and one
upper- body-targeted). Varying combinations of the nine
resistance exercises in each of these mesocycles will be
prescribed each session. After the initial 8 weeks of
training, participants will be progressively taught to per-
form the concentric (lifting) phase of all lower body ex-
ercises at high velocity. This is designed to improve
movement speed and muscle power. When possible, par-
ticipants will perform resistance exercises standing with
the aim to also improve balance and physical function.
Weight-bearing, impact exercise
For the weight-bearing, impact-loading exercises, partici-
pants will be prescribed three exercises (interspersed
amongst the PRT exercises) consisting of three sets of
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) diagram
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10–20 repetitions that will utilise body weight as the pri-
mary load. The programme will focus on lower-limb ex-
ercises designed to load the hips. The exercises
prescribed will be based on a battery that we have previ-
ously shown to be safe and effective for improving fem-
oral neck and lumbar spine aBMD in older men [54].
This battery includes a range of exercises from low to
high intensity (magnitude of peak ground reaction
forces) and difficulty (easy, moderate, hard) and is di-
vided into three broad categories: stationary movements
(e.g. marching on the spot, mini-tuck jumps), forward/
backwards movements (e.g. forward bench step-ups,
drop jumps) and lateral movements (e.g. side-to-side
jumping). Training intensity will be increased progres-
sively by increasing the height of jumps, by adding add-
itional weight, increasing the rate of impact-loading or
multi-directional movement patterns (e.g. diagonal loads).
Challenging balance/functional exercise
Challenging balance and functional exercises will include
a range of static and dynamic exercises, including fit ball
exercises (e.g. sitting on fit-ball with knee extension),
standing balance activities (e.g. single-leg standing) and
dynamic functional tasks (e.g. heel-to-toe walking). Par-
ticipants will be prescribed two exercises per session and
asked to complete two sets of 30–60 s or for a given
number of repetitions. To ensure progression, partici-
pants will be prescribed a new exercise or advance to a
more challenging level (e.g. closing eyes, reducing base
of support, confounding visual fixation, changing centre
of mass or adding a second manual or cognitive task)
once they have mastered the previous exercise (e.g. it is
no longer challenging).
Core stabilisation exercise
Key muscle groups known to help maintain good pos-
ture, improve pelvic floor function and trunk stability
(e.g. rotator cuff, scapular stabilisers, transverse abdom-
inis, pelvic floor muscles) will be targeted with these ex-
ercises, which are important for balance and muscular
performance [56]. Participants will be prescribed two ex-
ercises per session with light to moderate resistance in
two sets of 10 to 15 repetitions. Of note, abdominal-
based exercises will be prescribed in two sets of up to 50
repetitions.
Home-based exercise programme
The home-based exercise programme will consist of
similar types of exercise to the gym-based sessions, but
body weight and resistive tubing (provided to partici-
pants) will be used for resistance exercises. This will pro-
vide participants with knowledge and experience of ways
to exercise relatively inexpensively in a home-based set-
ting following the completion of the study. The home-
based programme will be explained and demonstrated to
the participants during the initial gym-based sessions
and instructions will be provided. Three resistance exer-
cises, three weight-bearing, impact-loading exercises and
three functional exercises following the same training
principles as gym-based sessions will be prescribed for
each home-based session. The home-based programme
will be progressed and new exercises will be introduced
once the previous exercises are no longer challenging for
the participant.
Nutritional supplement
The nutritional supplement will consist of a daily whey-
protein-, calcium- and vitamin D-enriched drink (pow-
der) combined with a single vitamin D tablet. Partici-
pants will be provided with 6-monthly supplies of
powder in single-use sachets and tablets. Each sachet is
to be mixed with 150 ml of water and shaken vigorously
in a ‘shake-and-take’ container (provided to participant).
Each sachet of powder will contain approximately 25 g
of whey-protein concentrate 80% (WPC80), containing
approximately 2.4 g of leucine, 1200 mg calcium carbon-
ate (~ 480 mg elemental calcium) and 1000 IU vitamin
D (Omniblend, Campbellfield, VIC. Australia). The vita-
min D tablet will contain 1000 IU (Ostelin, Macquarie
Park, NSW, Australia). On the non-training days, partic-
ipants will be asked to take one sachet every morning
before breakfast. This is designed to try and ensure a
more even protein intake throughout the day which has
been reported to optimise muscle protein balance [57].
On exercise training days, participants will be encour-
aged to consume the sachet within 1–2 h of completing
their exercise session as early post-exercise consumption
of protein has been shown to promote an increase in
MPS and muscle hypertrophy in older adults [58, 59].
Usual-care control group
Participants allocated to usual care will receive ongoing
care from their physician/specialist but will not receive
additional education or access to exercise training or the
protein-, calcium- and vitamin D-enriched nutritional
supplement powder sachet. Due to current practice
guidelines [40] and a pilot study we conducted in 31
men undergoing ADT for PCa in which 65% reported
taking vitamin D supplementation (90% at least 1000
IU/day), all men randomised to usual care will receive
1000 IU vitamin D per day. There is no evidence that
vitamin D alone (without calcium supplementation) at
these doses can prevent bone loss in these men [40].
Measurements
All measures will be collected at baseline, 26 and 52
weeks. Additionally, 24-h food recalls will also be admin-
istered at 13 and 39 weeks to monitor any habitual
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fluctuations in dietary factors. With the exception of
blood samples, 24-h food recalls and questionnaires, all
data will be collected at Deakin University. Blood sam-
ples will be collected at an external commercial path-
ology clinic. The 24-h food recalls will be administered
via telephone. Questionnaires will be completed by par-
ticipants at home prior to each testing sessions (i.e. base-
line, 26 and 52 weeks) and checked by the research staff
during these face-to-face testing sessions. A summary of
the proposed outcome measures is shown in Table 2. All
participants will undergo all measures expect those spe-
cific to treatment allocation (i.e. compliance to the inter-
vention). All data collected will be in a continuous
format, aside from the outcomes from some of the ques-
tionnaires, which will be categorical in nature.
Primary and secondary outcome measures
The primary outcome for this study will be changes in
proximal femur and lumbar spine aBMD. Secondary
outcomes will comprise: changes in 4% and 66% tibial
and radial vBMD, bone structure and strength, total
body and regional body composition, muscle strength,
functional capacity, cardiometabolic health, inflamma-
tory biomarkers, HR-QoL and cognitive function.
Bone mineral density
Total hip, femoral neck and lumbar spine (L1–L4)
aBMD (g/cm2) will be assessed using DXA (Lunar Prod-
igy, GE Lunar Corp., Madison, WI, USA) using software
version 12.30.008. The short-term coefficient of variation
(CV) for aBMD measures range from 0.6 to 1.0% within
our laboratory.
Volumetric BMD, bone geometry and strength
Proximal (66%) radial and tibial cortical vBMD (mg/
cm3), cortical area (mm2), total bone area (mm2), medul-
lary area (mm2) and polar Strength Strain Index (SSIpo-
lar, mm3), and distal (4%) radial and tibial total and
trabecular vBMD (mg/cm3), total bone area (mm2) and
the Bone Strength Index (BSI, mg2/mm4) of the non-
dominant upper limb and dominant lower limb will be
assessed using pQCT (XCT 3000, Stratec Medizintech-
nik GmbH, Pforzheim, Germany). Briefly, tibial length
will be determined by measuring from the distal edge of
the medial malleolus to the medial joint cleft of the knee
and radial length will be determined by measuring ulnar
length from the ulnar styloid process to the olecranon.
After obtaining a scout-view slice of the distal endplate of
the radius or tibia, scans will be performed at the 4% and
66% sites. The slice thickness will be 1 mm and voxel size
will be 0.5 mm at a scanning speed of 20 mm/s. All pQCT
bone and body composition parameters will be assessed
using BoneJ [60] ImageJ-plugin (rsbweb.nih.gov/ij) as pre-
viously reported [61]. Distal radial and tibial (4%) total
bone area and density will be analysed based on threshold-
ing at 169 mg/cm3, with trabecular density assessed using
a threshold of 480 mg/cm3. BSI will be calculated as fol-
lows: BSI = total area multiplied by the square of total
vBMD [62]. For the proximal radius and tibia (66%), the
periosteal surface will be determined based on a
threshold of 280 mg/cm3, and cortical bone a thresh-
old of 710 mm/cm3. Medullary area will be calculated
by subtracting cortical area from total area. SSIpolar
will be determined using the bone threshold of 480
mg/cm3 [63]. The short-term CVs for repeated mea-
sures in a sample of healthy premenopausal women
range from 0.9 to 2.2% for the 4% radius, 0.7 to 2.5%
for the 4% tibial and 0.6 and 1.8% for the 66% tibial
outcome measures [64].
Body composition
Total and regional (arms and legs) LBM (kg), FM (kg)
and percentage body fat will be assessed by DXA as de-
scribed above. The short-term CV for LBM and FM re-
peated measures range from 1.0 to 1.7% within our
laboratory. Muscle and subcutaneous fat cross-sectional
area (CSA) and muscle density (as a measure of inter-
muscular adiposity) at the proximal (66%) radius and
tibia will be assessed using pQCT. Thresholds of − 40 to
+ 40 mg/cm3 hydroxyapatite density will be used for es-
timating subcutaneous fat CSA. Muscle CSA will be esti-
mated by subtracting the total bone CSA and
subcutaneous fat CSA from the total area of the 66%
tibia or radius. The following CVs have been reported
for muscle CSA (radius, 2.1 to 5.3%; tibia, 2.5 to 3.7%),
muscle density (radius, 1.4 to 3.2%; tibia 0.7 to 3.2%) and
subcutaneous fat CSA (radius, 2.4 to 3.2%; tibia, 6.0 to
6.3%) for repeated measures in a sample of postmeno-
pausal women [65].
Muscle strength
Muscle strength will be obtained via chest press
(BodySolid, Powerline Smith Machine PSM144X, Forest
Park, IL, USA), leg press (Synergy Omni Leg Press S-31-
OPD, Yatala, QLD, Australia) and seated row (Nautilus
tower pulley system, F3ATFS, Independence, VA, USA)
three-repetition maximum (3-RM) protocols [53]. The
3-RM protocols assess the maximum weight that can be
lifted for three repetitions while maintaining correct
form and technique and were selected rather than one-
repetition maximum protocols to reduce participant ex-
ertion. Prior to attempting these protocols, participants
will complete a 5-min aerobic warm-up. Thereafter, each
participant will perform a warm-up set of eight to 10
repetitions with a light load. The participant will then
complete six to eight repetitions at a heavier weight. The
load will be increased incrementally until only three rep-
etitions can be completed. A 2–3-min recovery period
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Table 2 Summary of data collection
Variables Data collection method Data collection points
Baseline 26
weeks
52
weeks
Primary outcome measures
Areal bone mineral density DXA proximal femur and lumbar spine x x x
Secondary outcome measures
Bone structure and strength pQCT scan at 4% and 66% radial and tibial site x x x
Body composition DXA total body and regional lean mass, fat mass and % body fat x x x
pQCT 66% radial and tibial muscle cross-sectional area and muscle density x x x
Muscle strength Chest press, leg press and seated row x x x
Grip strength x x x
Functional capacity 30-s sit-to-stand x x x
Timed-up-and-go with cognitive task x x x
Four-square step test x x x
Berg balance scale x x x
Four-metre usual walk x x x
400-metre walk x x x
Biochemistry and lipids Overnight, fasted serum and plasma collection x x x
Inflammatory markers Overnight, fasted serum and plasma collection x x x
Blood pressure Automated measurement x x x
Cognitive function CogState Brief Battery computerised tests x x x
Rey Auditory Verbal Learning Test x x x
Trail Making Test (Part A and B) x x x
Digit Span Test x x x
National Adult Reading Test x
Health-related quality of life, fatigue
and mood
Functional Assessment of Cancer Therapy-Fatigue questionnaire x x x
Functional Assessment of Cancer Therapy-Prostate questionnaire x x x
Assessment of Quality of Life 8D questionnaire x x x
Geriatric Depression Scale questionnaire x x x
Depression Anxiety and Stress Scale questionnaire x x x
Additional measures
Anthropometry Height, weight, Body Mass Index, waist and hip circumference x x x
Habitual physical activity Community Healthy Activities Model Programme for Seniors physical activity
questionnaire
x x x
Diet 24-h food recalls Collected every 13 weeks
Additional questionnaire Demographic questionnaire x
Clinical and lifestyle questionnaire x x x
Sun exposure habits and practices questionnaire x x x
Alcohol consumption questionnaire x x x
Medical questionnaire x x x
Medication questionnaire x x x
Falls questionnaire x x x
Exercise programme adherence Calculated from monthly calendars collected every 4 weeks Collected every 4 weeks
Supplement compliance Calculated from supplement returned at 26 and 52 weeks x x
Adverse events Calculated from monthly calendars collected every 4 weeks Collected every 4 weeks
DXA dual-energy X-ray absorptiometry, pQCT peripheral quantitative computed tomography
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will be provided between each set. The 3-RM result will
be used in a formula to calculate each participant’s one-
repetition maximum [66]. The 3-RM protocol has been
shown to have a test-retest intraclass correlation coeffi-
cient (ICC) of 0.97 in a sample of untrained men [67]
and strongly correlates with 1-RM results [68].
Maximal muscle (grip) strength will be assessed using
a digital grip-strength dynamometer (Jamar Plus Digital,
Lafayette Instrument Company, IN, USA) [69]. The par-
ticipant will be seated with their foreman resting on the
arm of chair while maintaining a 90° angle at the elbow.
Participants will be asked to squeeze the dynamometer
maximally. Six trials will be completed (three with each
hand alternating) with the single highest score recorded.
A CV of 6.3% was reported for grip-strength repeated
measures with the same device in a sample of advanced
lung and gastrointestinal cancer patients [70].
Functional capacity
Functional capacity will be assessed using the 30-s sit-
to-stand, timed-up-and-go (TUG) with cognitive task
test, the four-square step test, the Berg Balance Scale,
the 4-m usual walk and the 400-m walk. The 30-s sit-to-
stand, four-square step test and 4-m usual walk will be
performed in triplicate, with the best result recorded. All
other tests will be performed once.
The 30-s sit-to-stand test measures lower-limb muscle
strength and function [71]. Participants begin in a seated
position with their arms folded across their chest on a
chair without arms. Participants are instructed to stand
fully upright and then return to a seated position as
many times as possible in 30 s. This test was observed
to have a test-retest ICC of 0.84 in a sample of
community-dwelling men aged 60 years and over [71].
The TUG with cognitive task test is a measure of dy-
namic balance and dual-tasking [72]. Participants will be
seated in a chair (height 45 cm) that will be placed at
the end of a 3-m walkway. Once instructed to begin, the
participant will stand up, walk at a regular pace for 3 m,
turn, walk back to the chair and sit down. During this
task, the participant will be provided with a mental
arithmetic task (e.g. counting backwards from 100 by 3’s
from a random number) and the number of correct
digits will be recorded. A stopwatch will be used to rec-
ord the time taken (to the nearest ms) to complete each
test. This test was observed to have an interrater ICC of
0.99 [73].
The four-square step test is a measure of dynamic bal-
ance and stepping speed in four directions [74]. Partici-
pants will be instructed to step forward, sideways, and
backwards over four canes resting flat on the floor in a
cross formation in a clockwise sequence and then back
to in an anticlockwise sequence. The participant will be
instructed to complete the test as fast as possible
without touching the raised canes, and to face forward
during the entire sequence. They will also be instructed
to ensure that both feet make contact with the floor in
each square. The time (to the nearest ms) taken to
complete the sequence will be measured with a stop-
watch. This test has been observed to have an interrater
and test-retest ICC of 0.99 and 0.98, respectively, in a
sample of community-dwelling adults aged 65 years and
over [74].
The Berg Balance Scale is an overall measure of bal-
ance including both dynamic and static components
[75]. The test rates participants on 14 different tasks on
an ordinal scale ranging from zero (unable to perform
the task) to 4 (performs the task independently). Assess-
ments include variations of sitting, standing, reaching,
leaning, turning and stepping. The scores of the 14 tasks
are summed to produce a total score ranging from 0 to
56 points. Higher scores indicate better performance.
This test was observed to have an interrater and test-
retest ICC of 0.98 and 0.97, respectively, in a sample of
adults aged 65 years and over [75].
The 4-m usual walk is a measure of gait speed [76].
Participants will be instructed to walk at a usual pace be-
tween two cones 8 m apart (2-m acceleration zone, 4-m
timed zone and 2-m deceleration zone). Time will be re-
corded when the participant’s front foot enters the timed
zone and stopped when their front foot exits the timed
zone. The time (to the nearest ms) to complete the
timed zone was recorded with a stopwatch. This method
has an ICC of 0.96 within our laboratory.
The 400-m walk test provides an estimate of cardiore-
spiratory fitness [77]. Participants will be instructed to
walk as fast as possible between two cones placed 20 m
apart (turning when they approach each cone). The time
(to the nearest ms) taken to complete 10 laps (400 m) will
be recorded. This test was observed to have a test-retest
ICC of 0.95 in a sample of middle-aged women [78].
Biochemical, lipid and lipoprotein measures
Fasted, resting, morning blood samples will be collected at
a commercial pathology clinic and sent to a central la-
boratory accredited by the National Association of Testing
Authorities Royal College of Pathologists Australasia. The
following parameters will be assessed using standardised
techniques: creatinine, albumin, inorganic phosphate and
corrected calcium. Fasting plasma glucose will be assessed
using the hexokinase method (Roche Diagnostics,
Mannheim, Germany). Total cholesterol, high-density
lipoprotein cholesterol and triglycerides will be deter-
mined using an enzymatic colorimetric method (Roche
Diagnostics, Mannheim, Germany). Low-density lipopro-
tein cholesterol will be calculated using Friedewald’s
formula. The estimated glomerular filtration rate (eGFR)
will be calculated using the participants’ serum creatinine,
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age and sex according to the abbreviated ‘modification of
diet in renal disease’ formula, which is now used by most
laboratories in Australia:
eGFR ml= min1:73m2
   ¼ 175 serum creatinine μmol=lð Þ  0:0113½ −1:154
age yearsð Þ−0:203
:
High-sensitivity C-reactive protein (CRP) will be
assessed using an immunoturbidimetric assay (Roche
Diagnostics, Mannheim, Germany). Total prostate-
specific antigen (free and complexed) will be assessed
via immunoassay (Roche Diagnostics, Mannheim,
Germany).
Serum aliquots will also be collected and stored at −
80 °C so that the following parameters can be assessed
in a single batch at the completion of the study if suffi-
cient funding is obtained: serum insulin, serum 25-
hydroxyvitamin D (25(OH)D), IGF-1, serum adiponectin
and resistin, and a battery of pro-inflammatory and anti-
inflammatory cytokines, including interleukin (IL)-6, IL-
1β, IL-8, tumour necrosis factor (TNF)-α and IL-10.
Blood pressure
Blood pressure will be assessed three times using an au-
tomated machine (TM-2655P, A&D, Tokyo, Japan) [79]
after a 10-min rest, with 1-min intervals between trials.
The mean of the second and third measures will be
used.
Cognitive function
Previous research has shown that ADT use is associated
with cognitive decline, particularly in the domains of
verbal memory, visuomotor function, attention and ex-
ecutive function [80]. Thus, this study will include a
number of established and valid cognitive tests to assess
the different cognitive domains. The CogState Brief Bat-
tery computerised test (http://cogstate.com/) will be ad-
ministered to assess cognitive function including
psychomotor function, attention, learning, reaction time,
processing speed, visual attention and working memory
[81, 82]. The CogState battery involves five compu-
terised tests (Groton maze, detection task, identification
task, one card learning task, one back task) conducted in
a quiet environment, with scripted instructions and a
practice attempt prior to completing each task.
The Rey Auditory Verbal Learning Test will be admin-
istered to assess memory and learning [83]. A list of 15
common words is read to the participant five times, with
the participant asked to immediately recall as many
words as possible following each recital. An interference
list is then presented, after which the participant must
recall words from the original list. Following a 20-min
delay, during which other non-verbal tests are con-
ducted, the participant is asked to recall the original list
again. Finally, the participant will be asked to visually
identify the words from the original list from a list of 50
words. Participants are scored on the total number of
words recalled in trials 1–5, total number recalled after
interference, loss after interference number (trial 5
minus trial 2) and long-delay free recall.
The Trail Making Test (Parts A and B) will be admin-
istered to assess executive function [84]. Participants will
be instructed to accurately draw lines to connect circled
numbers in sequential order as fast as possible (Part A).
Participants will then be instructed to draw lines to con-
nect circled numbers and letters in an alternating nu-
meric and alphabetic order (Part B).
The Digit Span Test measures working memory and
will be administered forwards and backwards to assess
short-term memory and working memory, respectively
[85]. In the first condition, the researcher presents the
participant with a string of non-sequential numbers
which gradually increase in length, which the participant
must then immediately recall in the same order in which
they were presented. In the second condition, the re-
searcher also presents the participant with a string of
non-sequential numbers which gradually increase in
length, but the participant must immediately recall them
in the reverse order to which they were presented.
The National Adult Reading Test will be administered
to calculate verbal, performance and full-scale
intelligence quotes as an estimate of cognitive reserve
[86]. The test comprises of 50 irregular words which are
read aloud by the participant. The number of errors re-
garding pronunciation are recorded.
Health-related quality of life, fatigue and mood
The Functional Assessment of Cancer Therapy-Fatigue
(FACT-F) [87] and the Functional Assessment of Cancer
Therapy-Prostate (FACT-P) [88] questionnaires will be
used to assess fatigue and HR-QoL, respectively. The
Assessment of Quality of Life 8D will also be used to as-
sess HR-QoL [89]. The Geriatric Depression Scale will
be used to assess depression [90]. The Depression Anx-
iety Stress Scale 21-item will be used to assess depres-
sion, anxiety, stress and psychological distress [91].
Anthropometry
Height and body mass will be assessed using a portable
stadiometer and scales, respectively. Body Mass Index
will be calculated using height and body mass. Girth
measurements of the chest, waist and hips will be
assessed using standard techniques.
Habitual physical activity
The Community Healthy Activities Model Programme
for Seniors physical activity questionnaire will be used to
assess participation in a comprehensive list of low,
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moderate and vigorous physical activities [92]. Participants
will document the frequency and duration of their partici-
pation in a ‘typical week’ of the preceding 4 weeks. The re-
sults will be reported as estimated kilojoules per week
spent in moderate- to high-intensity activities and hours
per week spent undertaking weight-bearing exercise.
Diet
Diet will be assessed using a 24-h food recall performed
during a one-on-one interview via telephone. Prior to
the telephone interview, the participant will complete a
24-h food diary with instructions that will be discussed
at the baseline testing session. These instructions will in-
clude how to use household measures (e.g. measuring
cups, plates, bowls, glasses) to help estimate food por-
tion sizes. In addition, a standard script will be used dur-
ing the telephone interview to maximise the ability of
participants to recall what was consumed. Dietary ana-
lysis will be performed using Australia-specific dietary
analysis software (FoodWorks, Xyris software, Highgate
Hills, QLD, Australia).
Additional questionnaires
A demographic, clinical and lifestyle questionnaire will
be used to obtain background information from partici-
pants (e.g. age, education history, marital status, employ-
ment status, cultural background, PCa and ADT-use
details). Sun-exposure habits and practices, alcohol con-
sumption, past and current medical conditions, use of
prescription and non-prescription medication (type and
dose) and falls and fracture history will also be included
in the questionnaire.
Compliance
Compliance with the exercise training programme (i.e.
attendance at each training session) and nutritional sup-
plement (i.e. consumption) will be assessed via attend-
ance record and self-reported diaries, respectively.
Diaries will be monitored weekly and calendars will be
monitored monthly by the participant’s accredited exer-
cise physiologist and researchers. In addition to the cal-
endars, compliance with the sachets and vitamin D
tablets will be checked by counting all returned at the
26- and 52-week testing sessions.
Adverse events
Any adverse events potentially associated, or confirmed to
be associated, with the exercise programme or protein,
calcium and vitamin D supplementation will be recorded
by the exercise trainers at each exercise training session
for the intervention-group participants and monthly tele-
phone calls by the research staff to the control-group par-
ticipants. For this trial, an adverse event will consist of any
health-related unfavourable or unintended medical
occurrence (e.g. sign, symptom, syndrome, illness) that de-
velops or worsens during the trial. All adverse events will
be assessed for seriousness, causality and expected out-
come by the researchers and followed during the trial. Al-
though there will be no formal data monitoring
committee, all data will be reviewed at regular intervals
throughout the study and researchers involved in recruit-
ment, testing and implementing the trial will update the
research team monthly about the study progress.
Data management and archiving
All data will be stored on password-protected com-
puters and in locked filing cabinets at Deakin Univer-
sity (Burwood). All study-related documents will be
archived at Deakin University at the end of the study for 7
years which is in line with current ethical requirements.
Dissemination plan
Findings from the primary outcomes of this trial will be
reported in journal articles, which will include results re-
gardless of the direction or magnitude of the effect. The
results will also be presented at leading national and
international conferences, clinical forums and to other
relevant health professionals and stakeholders, as well as
to the participants. All investigators will have the oppor-
tunity to be listed as an author of future publications in
accordance with journal-specific guidelines.
Sample size calculation
The sample size calculations are based on our previous re-
search in healthy and ADT-treated men. The mean (stand-
ard deviation (SD)) annual loss in femoral neck, hip and
spine BMD in ADT-treated men was 3.0% (4.5), 2.6% (2.8)
and 3.9% (3.0), respectively [14]. Our previous exercise tri-
als in healthy older men have shown that 12 months of
training can increase spine aBMD by 1.5–2.0% (SD 2.9)
and hip aBMD by 1.2–1.8% (SD 2.8) [39, 55]. We estimate
a conservative net difference in aBMD in favour of the
intervention of ~ 3.5–4.0% at the hip and spine. Based on
these estimates, 29 men in each group will provide 90%
power (P < 0.05, two-tailed) to detect a difference of this
magnitude (assuming a SD of 4.0). A net benefit of this
magnitude is clinically relevant as there is evidence that a
1–2% gain in aBMD translates into a 7–14% reduction in
fracture risk [36, 93]. For pQCT bone measures, radial and
tibial cortical area decreased by 11.5% (8.8) and 12.5%
(7.4), respectively, over 12 months in ADT-treated men
[14]. While few long-term trials have examined the effect
of exercise training on pQCT bone geometry in older men,
several intervention trials in older adults have shown that a
targeted, weight-bearing, impact-exercise programme can
have beneficial effects on cortical bone [94, 95]. Assuming
that the proposed intervention can half the rate of loss in
cortical area, we estimate that we will require 39 men per
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group (SD 8.0; 90% power, two-tailed, P < 0.05). Based on a
previous study and a meta-analysis showing that ADT is
associated with an average 7.7% gain in fat and a 2.8% loss
in lean mass over 3–12 months [96, 97], and that exercise
training can prevent the gain in FM and increase (1–5%)
or preserve LBM relative to usual care in men on ADT
[30, 32], we estimate a sample size of 24–32 in each group
will be required to observe a preservation in LBM and FM
in the intervention group vs. usual care (90% power, two-
tailed, P < 0.05). Assuming a conservatively projected 30%
dropout, an estimated sample size of 51 men per group
(102 in total) will be required. Based on previous studies in
ADT-treated men focussing on a number of our secondary
outcomes [32, 37, 98], we estimate that we will have suffi-
cient power (80–90%, P < 0.05, two-tailed) to detect the fol-
lowing intervention effects: 20–40% for muscle strength;
8–22% for functional capacity; 4 points for fatigue (FACT-
F), 15% for fasting plasma glucose and 14% for serum IL-6
and 20% for CRP. We will also have sufficient sample to
detect a clinically meaningful difference of 0.5 SD in the
Assessment of Quality of Life 8D questionnaire (AQoL-
8D) and 9 points on the FACT-P (disease-specific QoL).
Statistical analysis
Primary analyses will be conducted on an intention-to-
treat basis using STATA statistical software (STATA,
College Station, TX, USA). Per-protocol analysis will also
be performed by including all participants who are at least
66% compliant to the exercise (two of three sessions per
week) and 80% compliant to taking the supplements. Ini-
tially, descriptive statistics will be computed to compare
the intervention and usual-care groups on background
variables and baseline measures. All data will be screened
for outliers and the normality of the distribution of all data
will be assessed using Kolmogorov-Smirnov tests, with
skewed data log transformed prior to analysis. Linear
mixed models with random effects will be used to evaluate
the effects of the intervention compared to usual control.
Potential covariates to be included will be: age, duration of
ADT use, other chronic conditions, change in medication
and change in habitual physical activity or diet. Where
possible, we will obtain endpoint measures from all with-
drawals and include all randomised subjects in the final
analysis. For participants who are lost to follow-up, miss-
ing data will be handled with multiple imputation, with
subsequent sensitivity analyses to evaluate the effect of po-
tential non-random attrition. Baseline measures and
changes in outcome variables will be presented as means
± SD or 95% confidence intervals. A significance level of
P < 0.05 will be adopted for all statistical tests.
Discussion
This trial will be the first to assess the efficacy of
combining a targeted, bone-specific, resistance and
impact exercise training programme with nutritional
supplementation on musculoskeletal health in men
treated with ADT for PCa. Importantly, this is one of
the few known trials to examine such a lifestyle inter-
vention over an extended period of time (52 weeks)
in this population group, with a focus on both DXA
areal bone density and pQCT measures of bone
structure and cortical and trabecular volumetric
BMD, all of which are important determinants of
whole bone strength. There are currently no estab-
lished guidelines for specifically managing the large
range of adverse effects observed in men treated with
ADT [28]. Current guidelines mainly focus on
pharmacological interventions for bone health, such
as antiresorptive therapy with bisphosphonates, which
have been extensively evaluated and shown to prevent
losses in bone density commonly reported with ADT
[11, 99–101]. However, these drugs have no effect on
ameliorating the many other adverse effects associated
with ADT. In terms of muscle health, functional cap-
acity and cardiometabolic risk, the guidelines are less
evidence-based within this specific clinical population
group [11, 99], and commonly recommend more generic
exercise guidelines for cancer survivors [102–105]. A re-
cent study evaluating the most robust ADT-specific
guidelines [11] in a cohort of 113 men commencing
ADT concluded that over a 2-year follow-up, despite
maintaining bone density at the lumbar spine and redu-
cing various cardiometabolic risk markers via additional
therapies (e.g. statins), bone losses were still reported at
the total hip, and risk factors of cardiometabolic risk, such
as waist circumference, increased. Therefore, further well-
designed, long-term trials are needed to inform ADT-
specific exercise training guidelines for managing bone
health and cardiometabolic risk. Furthermore, there are
limited guidelines on addressing declines in HR-QoL and
the large range of additional ADT-induced adverse effects.
We expect that the findings from this study will provide a
unique opportunity to explore whether combining exer-
cise training with nutritional supplementation may also be
effective at ameliorating multiple ADT-induced adverse
effects when compared to usual care.
Trial status
The IMPACT trial is concurrently recruiting and
administering the intervention to a number of
participants.
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